Breast Cancer Metabolism

  • Jessica Tan
  • Anne LeEmail author
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 1063)


Despite advances in screening, therapy, and surveillance that have improved survival rates, breast cancer is still the most commonly diagnosed cancer and the second leading cause of cancer mortality among women [1]. Breast cancer is a highly heterogeneous disease rooted in a genetic basis and reflected in clinical behavior. The diversity of breast cancer hormone receptor status and the expression of surface molecules has guided therapy decisions for decades; however, subtype-specific treatment often yields diverse responses due to varying tumor evolution and malignant potential. Although understanding the mechanisms behind breast cancer heterogeneity is still a challenge, available evidence suggests that studying its metabolism has the potential to give valuable insight into the causes of these variations, as well as viable targets for intervention.


Breast cancer Estrogen receptor status Metabolic fingerprint Choline metabolism Estrogen metabolism Serine biosynthesis Glycolytic upregulation 









Choline kinase








Estrogen receptor


Glucose transporter


Glutathione S-transferase P


Human epidermal growth factor receptor 2




Phosphoglycerate dehydrogenase


Progesterone receptor


Phosphoserine aminotransferase 1


Phosphoserine phosphatase




Tricarboxylic acid


Triple-negative breast cancer


  1. 1.
    Gutierrez, T., et al. (2013). IL-21 promotes the production of anti-DNA IgG but is dispensable for kidney damage in lyn(−/−) mice. European Journal of Immunology, 43(2), 382–393.CrossRefPubMedGoogle Scholar
  2. 2.
    Hu, X., et al. (2009). Genetic alterations and oncogenic pathways associated with breast cancer subtypes. Molecular Cancer Research, 7(4), 511–522.CrossRefPubMedGoogle Scholar
  3. 3.
    Birnbaum, D. J., et al. (2011). Genome profiling of pancreatic adenocarcinoma. Genes, Chromosomes & Cancer, 50(6), 456–465.CrossRefGoogle Scholar
  4. 4.
    Son, J., et al. (2013). Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. Nature, 496(7443), 101–105.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Lyssiotis, C. A., et al. (2013). Pancreatic cancers rely on a novel glutamine metabolism pathway to maintain redox balance. Cell Cycle, 12(13), 1987–1988.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Telang, S., et al. (2007). The oncoprotein H-RasV12 increases mitochondrial metabolism. Molecular Cancer, 6, 77.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    White, E. (2013). Exploiting the bad eating habits of Ras-driven cancers. Genes & Development, 27(19), 2065–2071.CrossRefGoogle Scholar
  8. 8.
    Martinez-Outschoorn, U. E., et al. (2012). BRCA1 mutations drive oxidative stress and glycolysis in the tumor microenvironment: Implications for breast cancer prevention with antioxidant therapies. Cell Cycle, 11(23), 4402–4413.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Warburg, O., Wind, F., & Negelein, E. (1927). The metabolism of tumors in the body. The Journal of General Physiology, 8(6), 519–530.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Vander Heiden, M. G., Cantley, L. C., & Thompson, C. B. (2009). Understanding the Warburg effect: The metabolic requirements of cell proliferation. Science, 324(5930), 1029–1033.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Gatenby, R. A., & Gillies, R. J. (2004). Why do cancers have high aerobic glycolysis? Nature Reviews. Cancer, 4(11), 891–899.CrossRefPubMedGoogle Scholar
  12. 12.
    Waki, A., et al. (1998). The importance of glucose transport activity as the rate-limiting step of 2-deoxyglucose uptake in tumor cells in vitro. Nuclear Medicine and Biology, 25(7), 593–597.CrossRefPubMedGoogle Scholar
  13. 13.
    Choi, J., Jung, W. H., & Koo, J. S. (2013). Metabolism-related proteins are differentially expressed according to the molecular subtype of invasive breast cancer defined by surrogate immunohistochemistry. Pathobiology, 80(1), 41–52.CrossRefPubMedGoogle Scholar
  14. 14.
    Grover-McKay, M., et al. (1998). Role for glucose transporter 1 protein in human breast cancer. Pathology Oncology Research, 4(2), 115–120.CrossRefPubMedGoogle Scholar
  15. 15.
    Lloyd, S. M., Arnold, J., & Sreekumar, A. (2015). Metabolomic profiling of hormone-dependent cancers: A bird’s eye view. Trends in Endocrinology and Metabolism, 26(9), 477–485.CrossRefPubMedGoogle Scholar
  16. 16.
    Katz-Brull, R., et al. (2002). Metabolic markers of breast cancer: Enhanced choline metabolism and reduced choline-ether-phospholipid synthesis. Cancer Research, 62(7), 1966–1970.PubMedPubMedCentralGoogle Scholar
  17. 17.
    Eliyahu, G., Kreizman, T., & Degani, H. (2007). Phosphocholine as a biomarker of breast cancer: Molecular and biochemical studies. International Journal of Cancer, 120(8), 1721–1730.CrossRefPubMedGoogle Scholar
  18. 18.
    Aboagye, E. O., & Bhujwalla, Z. M. (1999). Malignant transformation alters membrane choline phospholipid metabolism of human mammary epithelial cells. Cancer Research, 59(1), 80–84.PubMedGoogle Scholar
  19. 19.
    Hilvo, M., et al. (2011). Novel theranostic opportunities offered by characterization of altered membrane lipid metabolism in breast cancer progression. Cancer Research, 71(9), 3236–3245.CrossRefPubMedGoogle Scholar
  20. 20.
    Ramirez de Molina, A., et al. (2002). Increased choline kinase activity in human breast carcinomas: Clinical evidence for a potential novel antitumor strategy. Oncogene, 21(27), 4317–4322.CrossRefPubMedGoogle Scholar
  21. 21.
    Rodriguez-Gonzalez, A., et al. (2004). Choline kinase inhibition induces the increase in ceramides resulting in a highly specific and selective cytotoxic antitumoral strategy as a potential mechanism of action. Oncogene, 23(50), 8247–8259.CrossRefPubMedGoogle Scholar
  22. 22.
    Glunde, K., Bhujwalla, Z. M., & Ronen, S. M. (2011). Choline metabolism in malignant transformation. Nature Reviews. Cancer, 11(12), 835–848.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Fuhrman, B. J., et al. (2012). Estrogen metabolism and risk of breast cancer in postmenopausal women. Journal of the National Cancer Institute, 104(4), 326–339.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Cicatiello, L., et al. (2010). Estrogen receptor alpha controls a gene network in luminal-like breast cancer cells comprising multiple transcription factors and microRNAs. The American Journal of Pathology, 176(5), 2113–2130.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Acconcia, F., & Kumar, R. (2006). Signaling regulation of genomic and nongenomic functions of estrogen receptors. Cancer Letters, 238(1), 1–14.CrossRefPubMedGoogle Scholar
  26. 26.
    Jia, M., et al. (2016). Estrogen receptor alpha promotes breast cancer by reprogramming choline metabolism. Cancer Research, 76(19), 5634–5646.CrossRefPubMedGoogle Scholar
  27. 27.
    Devanesan, P., et al. (2001). Catechol estrogen conjugates and DNA adducts in the kidney of male Syrian golden hamsters treated with 4-hydroxyestradiol: Potential biomarkers for estrogen-initiated cancer. Carcinogenesis, 22(3), 489–497.CrossRefPubMedGoogle Scholar
  28. 28.
    Cavalieri, E., et al. (2000). Estrogens as endogenous genotoxic agents--DNA adducts and mutations. Journal of the National Cancer Institute. Monographs, 27, 75–93.CrossRefGoogle Scholar
  29. 29.
    Bradlow, H. L., et al. (1996). 2-hydroxyestrone: The ‘good’ estrogen. The Journal of Endocrinology, 150(Suppl), S259–S265.PubMedPubMedCentralGoogle Scholar
  30. 30.
    Possemato, R., et al. (2011). Functional genomics reveal that the serine synthesis pathway is essential in breast cancer. Nature, 476(7360), 346–350.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Fan, J., et al. (2015). Human phosphoglycerate dehydrogenase produces the oncometabolite D-2-hydroxyglutarate. ACS Chemical Biology, 10(2), 510–516.CrossRefPubMedGoogle Scholar
  32. 32.
    Rakheja, D., et al. (2013). The emerging role of d-2-hydroxyglutarate as an oncometabolite in hematolymphoid and central nervous system neoplasms. Frontiers in Oncology, 3, 169.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Terunuma, A., et al. (2014). MYC-driven accumulation of 2-hydroxyglutarate is associated with breast cancer prognosis. The Journal of Clinical Investigation, 124(1), 398–412.CrossRefPubMedGoogle Scholar
  34. 34.
    Yue, W., et al. (2003). Genotoxic metabolites of estradiol in breast: Potential mechanism of estradiol induced carcinogenesis. The Journal of Steroid Biochemistry and Molecular Biology, 86(3-5), 477–486.CrossRefPubMedGoogle Scholar
  35. 35.
    Mullarky, E., et al. (2016). Identification of a small molecule inhibitor of 3-phosphoglycerate dehydrogenase to target serine biosynthesis in cancers. Proceedings of the National Academy of Sciences of the United States of America, 113(7), 1778–1783.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Jerby, L., et al. (2012). Metabolic associations of reduced proliferation and oxidative stress in advanced breast cancer. Cancer Research, 72(22), 5712–5720.CrossRefPubMedGoogle Scholar
  37. 37.
    Shen, L., et al. (2015). Metabolic reprogramming in triple-negative breast cancer through Myc suppression of TXNIP. Proceedings of the National Academy of Sciences of the United States of America, 112(17), 5425–5430.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Jove, M., et al. (2017). A plasma metabolomic signature discloses human breast cancer. Oncotarget, 8(12), 19522–19533.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Huang, S., et al. (2016). Novel personalized pathway-based metabolomics models reveal key metabolic pathways for breast cancer diagnosis. Genome Medicine, 8(1), 34.CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Giskeodegard, G. F., et al. (2010). Multivariate modeling and prediction of breast cancer prognostic factors using MR metabolomics. Journal of Proteome Research, 9(2), 972–979.CrossRefPubMedGoogle Scholar
  41. 41.
    Mountford, C. E., et al. (2001). Diagnosis and prognosis of breast cancer by magnetic resonance spectroscopy of fine-needle aspirates analysed using a statistical classification strategy. The British Journal of Surgery, 88(9), 1234–1240.CrossRefPubMedGoogle Scholar
  42. 42.
    Asiago, V. M., et al. (2010). Early detection of recurrent breast cancer using metabolite profiling. Cancer Research, 70(21), 8309–8318.CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Oakman, C., et al. (2011). Identification of a serum-detectable metabolomic fingerprint potentially correlated with the presence of micrometastatic disease in early breast cancer patients at varying risks of disease relapse by traditional prognostic methods. Annals of Oncology, 22(6), 1295–1301.CrossRefPubMedGoogle Scholar
  44. 44.
    Jobard, E., et al. (2014). A serum nuclear magnetic resonance-based metabolomic signature of advanced metastatic human breast cancer. Cancer Letters, 343(1), 33–41.CrossRefPubMedGoogle Scholar
  45. 45.
    Simoes, R. V., et al. (2015). Metabolic plasticity of metastatic breast cancer cells: Adaptation to changes in the microenvironment. Neoplasia, 17(8), 671–684.CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Wei, S., et al. (2013). Metabolomics approach for predicting response to neoadjuvant chemotherapy for breast cancer. Molecular Oncology, 7(3), 297–307.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of PathologyJohns Hopkins University School of MedicineBaltimoreUSA
  2. 2.Department of Pathology and OncologyJohns Hopkins University School of MedicineBaltimoreUSA

Personalised recommendations